REMEDY PHARMACEUTICALS TO PRESENT AT THE OPPENHEIMER 26th ANNUAL HEALTHCARE CONFERENCE
NEW YORK, December 2, 2015 — Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of an innovative drug, CIRARA™, announced today that the Company will be presenting at the Oppenheimer 26th Annual Healthcare Conference to be held at the Westin Grand Central in New York City on December 8 – 9, 2015.
Sven Jacobson, Remedy Pharmaceuticals’ Chief Executive Officer, will present a formal company presentation, followed by a Q&A session, on Tuesday, December 8th in the Consulate Room at 9:10am – 9:40am ET.
CIRARA is a patented, high affinity inhibitor of Sur1-Trpm4 channels suitable for intravenous delivery at the bedside or even in an ambulance. CIRARA uses our proprietary, patented MPD™ technology. CIRARA is an investigational drug for severe stroke and is not approved by FDA.
ABOUT REMEDY PHARMACEUTICALS
Remedy Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on bringing life saving treatment to millions of people affected by acute central nervous system conditions -- including stroke, traumatic brain injury, spinal cord injury, as well as other ischemic injuries and neurological disorders.
Contact: Sven Jacobson
212-586-2226 x 225